title: The role of rubella-immunoblot and rubella-peptide-EIA for the diagnosis of the congenital rubella syndrome during the prenatal and newborn periods.
abstract: Rubella infection during the first trimester of pregnancy can cause the congenital rubella syndrome (CRS). Patients with CRS were shown to have a decreased humoral and cellular immunity. It is not known whether asymptomatic newborns who had experienced intrauterine infection with rubella virus (RV) differ in their antibody response from newborns with CRS. In this study we compared both groups for a difference which might be a useful diagnostic criterion for CRS during the prenatal and newborn periods. We used the nonreducing Rubella-Immunoblot and the Rubella-IgG-Peptide-Enzyme Immunoassay (EIA) to determine the antibodies directed to rubella proteins E1, E2 and C. The results showed that only newborns with CRS who had experienced RV infection during the first 12 weeks of gestation showed significantly reduced levels of antibodies directed to both the linear RV E1 epitope (SP 15) and the topographic RV E2 epitope. Asymptomatic newborns infected mostly later than week 10 of gestation showed normal levels of antibodies. These data suggest that the lack of antibody response in CRS is linked to the immaturity of the fetal immune system during the first trimester of gestation. Rubella-IgG-Peptide-EIA and Rubella-Immunoblot should be used additionally for CRS diagnosis in the prenatal/newborn periods. These results may have an impact on the early treatment of late-onset symptoms of CRS patients.
authors.affiliation: Virologisches Institut der Universität Leipzig, Germany.
authors.forename: K
authors.initials: K
authors.lastname: Meitsch
authors.forename: G
authors.initials: G
authors.lastname: Enders
authors.forename: J S
authors.initials: JS
authors.lastname: Wolinsky
authors.forename: R
authors.initials: R
authors.lastname: Faber
authors.forename: B
authors.initials: B
authors.lastname: Pustowoit
mesh_terms: D000914:Antibodies, Viral / Q000032:analysis*; D005260:Female; D006801:Humans; D015151:Immunoblotting; D007124:Immunoenzyme Techniques; D007074:Immunoglobulin G / Q000032:analysis; D007231:Infant, Newborn; D011247:Pregnancy; D011296:Prenatal Diagnosis; D012409:Rubella / Q000175:diagnosis* / Q000276:immunology; D012410:Rubella Syndrome, Congenital / Q000175:diagnosis* / Q000276:immunology; D014758:Viral Core Proteins / Q000276:immunology; D014759:Viral Envelope Proteins / Q000276:immunology
chemical_list: D000914:Antibodies, Viral; D007074:Immunoglobulin G; D014758:Viral Core Proteins; D014759:Viral Envelope Proteins; C074573:nucleocapsid protein (C), rubella virus; C040901:rubella antibodies; C061826:E1 envelope protein, Rubella virus; C061827:E2 envelope protein, Rubella virus